Abstract
The concept of mild cognitive impairment (MCI) was first introduced for the purpose of identifying individuals in an intermediate state between no cognitive impairment and Alzheimer’s disease (AD). Recently, the heterogeneity of MCI has attracted attention as it has become clear that other diseases, such as cerebrovascular disease and Parkinson disease can also cause mild cognitive deficits, prompting a redefinition of MCI. Heterogeneity of MCI has been confirmed by neuropathological examinations. Most MCI patients not only possess amyloid plaques and neurofibrillary tau tangles, but also cerebral vascular pathology such as arteriosclerosis and cerebral amyloid angiopathy (CAA). CAA induces cerebral infarcts or hemorrhage of varying size and type, attributing to further cognitive impairment. Sporadic AD and CAA has been suggested to be the consequence of Aβ elimination failure, mainly caused by disturbance of the perivascular drainage system. Since severe CAA is an independent risk factor for dementia, facilitation of Aβ clearance has been suggested as a potential treatment of AD and MCI. Many epidemiological studies have shown that vascular risk factors increase incidence of MCI and its progression to AD. Accordingly, control of such factors has been shown to reduce risk of conversion to AD and ameliorate cognitive impairment in AD patients. Neurovascular approaches may therefore hold promise for the treatment of dementia in an era of preventive neurology.
Keywords: Alzheimer’s disease, cerebral amyloid angiopathy, cerebrovascular disease, cilostazol, diagnosis, microinfarcts, mild cognitive impairment, neurocognitive disorder.
Current Alzheimer Research
Title:Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Volume: 12 Issue: 6
Author(s): Satoshi Saito, Yumi Yamamoto and Masafumi Ihara
Affiliation:
Keywords: Alzheimer’s disease, cerebral amyloid angiopathy, cerebrovascular disease, cilostazol, diagnosis, microinfarcts, mild cognitive impairment, neurocognitive disorder.
Abstract: The concept of mild cognitive impairment (MCI) was first introduced for the purpose of identifying individuals in an intermediate state between no cognitive impairment and Alzheimer’s disease (AD). Recently, the heterogeneity of MCI has attracted attention as it has become clear that other diseases, such as cerebrovascular disease and Parkinson disease can also cause mild cognitive deficits, prompting a redefinition of MCI. Heterogeneity of MCI has been confirmed by neuropathological examinations. Most MCI patients not only possess amyloid plaques and neurofibrillary tau tangles, but also cerebral vascular pathology such as arteriosclerosis and cerebral amyloid angiopathy (CAA). CAA induces cerebral infarcts or hemorrhage of varying size and type, attributing to further cognitive impairment. Sporadic AD and CAA has been suggested to be the consequence of Aβ elimination failure, mainly caused by disturbance of the perivascular drainage system. Since severe CAA is an independent risk factor for dementia, facilitation of Aβ clearance has been suggested as a potential treatment of AD and MCI. Many epidemiological studies have shown that vascular risk factors increase incidence of MCI and its progression to AD. Accordingly, control of such factors has been shown to reduce risk of conversion to AD and ameliorate cognitive impairment in AD patients. Neurovascular approaches may therefore hold promise for the treatment of dementia in an era of preventive neurology.
Export Options
About this article
Cite this article as:
Saito Satoshi, Yamamoto Yumi and Ihara Masafumi, Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction, Current Alzheimer Research 2015; 12 (6) . https://dx.doi.org/10.2174/1567205012666150530202508
DOI https://dx.doi.org/10.2174/1567205012666150530202508 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Discharge Interventions and Modifiable Risk Factors for Preventing Hospital Readmissions in Children with Medical Complexity
Reviews on Recent Clinical Trials Foods versus Drugs for Health Promotion: Considerations for Future Directions
Current Pediatric Reviews Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry New Copper Compounds with Antiplatelet Aggregation Activity
Medicinal Chemistry Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Protection by Natural Honey Against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Cardiovascular Disease and Diabetes in South Asians: The Twin Epidemic
Current Diabetes Reviews Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats
Current Gene Therapy The Molecular Mechanisms of Vascular Restenosis: Which Genes are Crucial?
Current Vascular Pharmacology Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery